Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure” | Alzheimer's Research & Therapy | Full Text

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure” | Alzheimer's Research & Therapy | Full Text



Alzheimer's Research & Therapy

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”

• Joshua D. GrillEmail authorView ORCID ID profile,
• Chelsea G. Cox,
• Kristin Harkins and
• Jason Karlawish

Alzheimer's Research & Therapy201911:51

https://doi.org/10.1186/s13195-019-0504-1

©  The Author(s). 2019

• Received: 30 April 2019
• Accepted: 13 May 2019
• Published: 4 June 2019

The goal of “Reactions to learning a ‘not elevated’ amyloid PET result in a preclinical Alzheimer’s disease trial” was to study how learning one is not eligible for a trial based on an Alzheimer’s disease (AD) biomarker result affects willingness to be in subsequent trials, as well as how it affects other behaviors [1]. Answering this question fills a critical gap in the literature, as preclinical AD trials are increasingly common but the ideal criteria for participant inclusion remains an area of active research. Thus, a person ineligible for one trial may be eligible for another.